Skip to main content

Bio-Rad's Clinical Dx Revenues Rise 18 Percent As Sales Improve Across the Board

NEW YORK (GenomeWeb News) — Bio-Rad Laboratories today said third-quarter revenues increased 11 percent as R&D spending rose 7 percent and profit jumped around 20 percent.
 
Total receipts for the three months ended Sept. 30 increased to $339.7 million from $304.8 million year over year.
 
Revenue from the company’s Clinical Diagnostics segment rose nearly 18 percent to $193.3 million as it experienced “strong growth across all product lines, particularly in quality control, auto-immune, diabetes, and blood virus testing products.”
 
Meantime, receipts from the Life Science division grew 4.1 percent to $143 million in part due to sales of its recently released ProteOn XPR36 protein interaction array system as well as the Bio-Plex suspension array systems and reagents.
 
R&D spending rose to $33.1 million from $31 million year over year.
 
Bio-Rad's profit jumped to $28 million from $23.2 million in the year-ago period.
 
Bio-Rad said it had around $472.8 million in cash and equivalents and $70.6 million in short-term investments as of Sept. 30.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.